Dilated cardiomyopathy

Silent Killers: Unveiling the Hidden Cardiac Pathologies Behind Sudden Cardiac Death

By MedXY 08/10/2026

This study reveals that two-thirds of community sudden cardiac deaths occur in individuals without diagnosed cardiac disease, with half harboring occult myocardial infarction or dilated cardiomyopathy, underscoring the need for improved detection strategies.

Cardiology news

Left Ventricular Hypertrabeculation in Dilated Cardiomyopathy: Prognostic Insights and Clinical Implications

By MedXY 08/07/2026

This study reveals that left ventricular hypertrabeculation, common in dilated cardiomyopathy, does not increase embolic risk or adverse outcomes, challenging previous concerns and guiding clinical management.

Cardiology news

RBM20 Truncating Variants in Dilated Cardiomyopathy: Reduced Penetrance and Milder Phenotype Compared to Missense Variants

By MedXY 04/28/2026

This study highlights the role of RBM20 truncating variants in arrhythmogenic dilated cardiomyopathy, showing reduced penetrance and milder disease severity compared to pathogenic missense variants and titin truncating variants.

Cardiology Clinical Updates news

Precision Medicine in Dilated Cardiomyopathy: Integrating Genetic Counselling and Testing into Clinical Practice

By MedXY 03/20/2026

This review explores the transition of genetic testing in dilated cardiomyopathy from family risk assessment to a central tool for clinical decision-making and personalized risk stratification.

Cardiology news

LOXL2 Inhibition: A New Frontier in Treating LMNA-Related Dilated Cardiomyopathy

By MedXY 03/17/2026

Recent research identifies LOXL2 as a primary driver of fibrosis in LMNA-mutated dilated cardiomyopathy. The study demonstrates that Simtuzumab, a LOXL2 inhibitor, effectively prevents extracellular matrix remodeling and preserves cardiac function in both human iPSC and murine models.

Cardiology news

Precision Targeting of the Sarcomere: Danicamtiv Shows Genotype-Specific Efficacy in Dilated Cardiomyopathy

By MedXY 01/16/2026

A Phase 2 trial demonstrates that danicamtiv, a novel cardiac myosin agonist, significantly improves left ventricular function in patients with genetic forms of dilated cardiomyopathy, particularly those with MYH7 and TTN variants, signaling a shift toward precision cardiology.

Cardiology news

Beyond the Mutation: Uncovering the Triggers of Disease Onset in Titin-Related Dilated Cardiomyopathy

By MedXY 01/03/2026

An international multicenter study reveals that while Titin-truncating variants significantly increase cardiomyopathy risk, disease onset is heavily influenced by male sex, co-morbidities, and atrial fibrillation, while early prophylactic therapy may offer substantial protection.

Cardiology news

Beyond Arrhythmia: High-Risk Genotypes in Dilated Cardiomyopathy Predict Progression to Advanced Heart Failure

By MedXY 01/03/2026

A landmark Spanish study reveals that patients with 'arrhythmic' genotypes in dilated cardiomyopathy face a significantly higher risk of advanced heart failure events, including heart transplantation and VAD implantation, necessitating a paradigm shift in clinical management.

Cardiology news

Caring for Families After a Dilated Cardiomyopathy Diagnosis: Practical Guidance from the 2025 Clinical Consensus

By MedXY 11/29/2025

A focused guide to modern genetic and clinical screening of relatives after a dilated cardiomyopathy diagnosis, summarizing the 2025 clinical consensus and practical steps for clinicians and families.

Cardiology Specialties

Sex-Specific Genetic Insights into Dilated Cardiomyopathy: The Key Role of Desmoplakin Variants

By MedXY 08/22/2025

Desmoplakin gene variants confer a higher risk and penetrance of dilated cardiomyopathy in females, contrasting with male-predominant risks from other genes like TTN. This discovery underscores sex-specific mechanisms in DCM susceptibility and prognosis.